Trust Signals
Every claim on this page is graded by evidence type. Speculative claims are labeled as such. No proprietary products are promoted. Sources are real, named, and listed at the bottom. Where exact figures are unavailable, qualitative ranges are used instead of invented numbers.
Key Takeaways
- Tesamorelin (Egrifta) is FDA-approved for visceral fat reduction in HIV-associated lipodystrophy, backed by phase 3 RCTs enrolling hundreds of patients.
- AOD 9604 corresponds to amino acids 177 to 191 of human GH and has GRAS food-ingredient status from 2014, but zero FDA drug approval and no large human RCT published.
- Tesamorelin raises IGF-1 and can cause fluid retention and arthralgias; AOD 9604 pilot data suggest minimal IGF-1 elevation, but this is low-quality evidence.
- Both are on the WADA prohibited list and would be flagged in anti-doping screens.
- For off-label general fat loss in metabolically healthy adults, neither has sufficient evidence to draw firm conclusions, but tesamorelin at least has a credible mechanism proven in humans.
Direct Answer: AOD 9604 vs Tesamorelin in 50 Words
Tesamorelin wins on every evidence metric that matters: it is FDA-approved, has published phase 3 human RCT data, and a clearly mapped mechanism through the GHRH receptor. AOD 9604 has only rodent and small pilot human data. If clinical evidence is your standard, tesamorelin is not close competition for AOD 9604.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How each peptide works: mechanism with specific details
- Evidence ledger: every major claim graded
- Honest head-to-head comparison table
- What most comparison pages get wrong
- The chemistry behind stability and storage rules
- Label and COA literacy: how to judge a product
- Side effect profiles compared
- Regulatory and anti-doping status
- Which peptide fits which situation
- FAQ
- Sources
How Does Each Peptide Actually Work?
Tesamorelin mechanism. Tesamorelin is a 44-amino-acid analogue of endogenous GHRH with a trans-3-hexenoic acid moiety attached to its N-terminus. That modification slows dipeptidyl peptidase IV (DPP-IV) cleavage, extending its functional half-life relative to native GHRH. It binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile GH secretion. The resulting GH elevation drives IGF-1 production in the liver, and both GH and IGF-1 promote lipolysis in visceral adipose tissue by activating hormone-sensitive lipase. This cascade is well-established human physiology, and phase 3 trials by Falutz et al. confirmed that it translates into measurable visceral adipose tissue (VAT) reduction by CT scan in HIV-associated lipodystrophy patients.
AOD 9604 mechanism. AOD 9604 corresponds to residues 177 to 191 of the human GH sequence, the region thought to be responsible for GH's lipolytic activity. The working hypothesis is that this fragment retains lipolytic and anti-lipogenic signaling independently of GH receptor binding at the full-length site, and therefore without driving IGF-1. The primary evidence for this comes from rodent obesity models published by researchers at Monash University in the late 1990s and early 2000s. A small clinical pilot in obese adults was conducted but results were not conclusive. The receptor target for AOD 9604 in humans is not definitively identified; the fragment may interact with beta-3 adrenergic receptors or undefined lipid metabolism pathways, but this remains mechanistically unresolved.
Evidence Ledger: Every Major Claim Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Tesamorelin reduces visceral fat in HIV lipodystrophy | Multiple human RCTs (Falutz 2007, 2010); phase 3 data | Positive, consistent | High |
| Tesamorelin raises IGF-1 above ULN in a proportion of patients | Phase 3 RCT adverse event data | Confirmed risk | High |
| Tesamorelin reduces VAT in metabolically healthy, non-HIV adults | Small exploratory human studies only | Plausible, unconfirmed | Low |
| AOD 9604 reduces fat mass in rodent models | Animal studies (Monash group, multiple) | Positive in rodents | Moderate (animal) |
| AOD 9604 reduces fat mass in humans | Small pilot studies; no large RCT | Inconclusive | Very Low |
| AOD 9604 does not raise IGF-1 meaningfully | Animal data, limited human pilot | Possibly favorable | Low |
| AOD 9604 is safe at therapeutic doses in humans | GRAS assessment (food use), small pilot tolerability data | No serious signals found, but dataset is small | Low |
| AOD 9604 improves cartilage or joint outcomes | In vitro cell studies, animal models | Preliminary positive signal | Very Low |
Honest Head-to-Head: Where Each Peptide Wins and Loses
| Category | AOD 9604 | Tesamorelin | Winner |
|---|---|---|---|
| FDA approval | None (GRAS food ingredient only) | Approved (Egrifta, 2010, HIV lipodystrophy) | Tesamorelin |
| Human RCT evidence for fat loss | No large RCT published | Multiple phase 3 RCTs | Tesamorelin |
| IGF-1 elevation risk | Low (pilot data, low confidence) | Confirmed risk in RCTs | AOD 9604 (tentative) |
| Mechanism clarity | Poorly defined in humans | Well-characterized GHRH receptor pathway | Tesamorelin |
| Cost to patient | Lower (research peptide market) | High without insurance; brand drug pricing | AOD 9604 |
| Regulatory risk for prescriber | High (not an approved drug) | Low when prescribed on-label | Tesamorelin |
| Fluid retention / arthralgias | Not reported in limited data | Documented in phase 3 trials | AOD 9604 (tentative) |
| WADA status | Prohibited (GH fragment) | Prohibited (GHRH analogue) | Neither |
| Evidence for non-lipodystrophy obesity | Animal only | Small exploratory only | Neither |
What Most Comparison Pages Get Wrong
The GRAS confusion. Many sites present AOD 9604's GRAS status as equivalent to a safety or efficacy endorsement for injectable use. It is not. GRAS applies to food-additive concentrations and oral exposure. An injectable preparation bypasses first-pass metabolism entirely, operates at different pharmacokinetics, and was never part of the GRAS assessment. The safety profile of an oral food ingredient tells you almost nothing about subcutaneous injection safety at therapeutic doses.
Conflating mechanism with proven effect. Pages routinely describe AOD 9604's proposed mechanism (stimulating beta-3 adrenergic receptors, inhibiting acetyl-CoA carboxylase) as established fact. These are hypotheses drawn from rodent data. The actual receptor target in humans has not been confirmed in a peer-reviewed trial. A plausible mechanism is not the same as evidence that the mechanism operates at the doses and routes used in human peptide protocols.
Presenting tesamorelin's approval as broadly applicable. Tesamorelin is approved for one specific indication: excess abdominal fat in HIV-infected adults with lipodystrophy. Its use for general weight loss or body composition optimization in metabolically healthy individuals is off-label and supported by substantially weaker evidence. The approval does not validate every use case promoted in wellness contexts.
Ignoring purity variance in the research peptide market. Compounded or "research grade" versions of both peptides, particularly AOD 9604, vary substantially in purity, peptide content, and sterility. A certificate of analysis from a third-party lab is the minimum check; even then, HPLC purity figures above 98% do not guarantee correct folding or absence of bioactive impurities.
The Chemistry Behind Storage and Stability Rules
Why tesamorelin degrades at room temperature. Like all peptides, tesamorelin is susceptible to hydrolysis of its amide bonds and oxidation of susceptible residues once in aqueous solution. The trans-3-hexenoic acid modification at the N-terminus blocks DPP-IV cleavage specifically, but does not protect against general aqueous degradation. Refrigeration (2 to 8 degrees Celsius) slows but does not stop these reactions. Reconstituted vials should be used the same day or within the window specified in the product labeling, not stored for days in a syringe.
Why freeze-thaw cycles matter for AOD 9604. AOD 9604 is a 16-amino-acid peptide with a disulfide bridge between residues corresponding to Cys182 and Cys189 in the native GH sequence. Repeated freeze-thaw cycles can promote disulfide scrambling and aggregation, reducing active peptide content without producing visible particulate. A solution that looks clear may have degraded meaningfully. Lyophilized powder is stable for considerably longer than reconstituted solution when stored cold and protected from light.
Bacteriostatic water vs sterile water for reconstitution. Bacteriostatic water (containing 0.9% benzyl alcohol) extends the usable life of a reconstituted peptide vial by suppressing microbial growth. Sterile water without preservative should be used for single-dose reconstitution only. Using sterile water in a multi-draw vial is a contamination risk, not a peptide stability problem, but the consequence can be infection at the injection site.
Label and COA Literacy: Judging a Product Yourself
For compounded tesamorelin or AOD 9604, request and read:
| Document Field | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Greater than 98% is standard; single peak | Purity below 95% or multiple peaks not explained |
| Mass spectrometry (MS) confirmation | Molecular weight matching theoretical value within 1 dalton | No MS data, or weight not matching expected |
| Endotoxin test | Below 5 EU/kg body weight per hour for injectables (USP standard) | No endotoxin result on COA |
| Sterility | USP sterility test passed, or compounded under 503B standards | "Research use only, not for human use" on injectable vials |
| Peptide content (not just purity) | Stated mg amount verified against actual peptide content | Only purity listed; mg amount unverified |
Dosing reference (for context only, not a prescription). In its approved indication, tesamorelin is dosed at 2 mg subcutaneously once daily. AOD 9604 doses used in research protocols have ranged from 250 mcg to 500 mcg per day subcutaneously in the limited human pilot literature, but no dose-response RCT in humans has established an optimal dose. These numbers are provided for context in evaluating products, not as clinical guidance.
Side Effect Profiles: What the Data Actually Show
Tesamorelin. Phase 3 trial data from Falutz and colleagues, published in peer-reviewed journals between 2007 and 2010, documented injection site reactions, peripheral edema, arthralgias, and myalgias as common adverse events. A proportion of patients showed IGF-1 levels above the upper limit of normal. Tesamorelin is contraindicated in patients with active malignancy (given IGF-1's mitogenic potential), in pregnancy, and in patients with disrupted hypothalamic-pituitary-adrenal axis. Glucose intolerance is a theoretical concern with sustained IGF-1 elevation, though the trial data did not show a major signal at one year.
AOD 9604. The limited human tolerability data suggest a relatively benign side effect profile at the doses tested, with no significant injection site reactions or metabolic disturbances reported in small studies. Because no large RCT exists, rare but serious adverse events would not be detectable in the available data set. The absence of evidence of harm is not the same as evidence of absence of harm when the database is this small.
Regulatory and Anti-Doping Status
The World Anti-Doping Agency (WADA) Prohibited List includes both categories relevant here. Tesamorelin falls under GHRH and its analogues, prohibited at all times in and out of competition. AOD 9604 falls under GH fragments and releasing factors, also prohibited at all times. Testing methods for GH peptides have become increasingly sensitive. Any competitive athlete considering either compound should be aware that a therapeutic use exemption would be required and is unlikely to be granted for non-approved indications.
In the United States, neither peptide can be legally marketed as a dietary supplement. Compounded versions of tesamorelin may be available through 503A or 503B pharmacies under a valid prescription for an appropriate patient. AOD 9604 does not have an approved drug application, so compounded versions exist in a legally ambiguous space. The FDA has issued guidance restricting certain peptides from compounding, and the regulatory status of AOD 9604 in compounding has been subject to regulatory attention.
Which Peptide Fits Which Situation?
Tesamorelin is the evidence-supported choice if: you are an HIV-positive adult with confirmed lipodystrophy, prescribed by an appropriately licensed provider, and access through a pharmacy. Outside this indication, you are working with off-label extrapolation from a strong mechanism and weak secondary evidence.
AOD 9604 remains experimental if: you are any adult seeking fat loss outside an approved clinical trial. The rodent data are interesting; the mechanism is plausible; the human evidence is insufficient to support confident use. The lower IGF-1 profile is a potentially meaningful differentiator, but this advantage is not yet proven at scale in humans.
For a skeptical clinician evaluating a patient asking about these peptides: the honest answer is that tesamorelin has proven efficacy in one specific population. For everyone else, including general body composition goals, neither peptide has the human evidence base to be recommended over diet, resistance training, or (for weight loss) FDA-approved pharmacotherapy with actual outcome data.
Frequently Asked Questions
What is the difference between AOD 9604 and tesamorelin?
Tesamorelin is an FDA-approved GHRH analogue with robust human RCT data showing visceral fat reduction in HIV-associated lipodystrophy. AOD 9604 is a synthetic fragment of human growth hormone with only animal and small human pilot data. They share a fat-reduction goal but differ enormously in evidence quality and regulatory status.
Is AOD 9604 FDA approved?
No. AOD 9604 received FDA GRAS status as a food ingredient in 2014, but it has never been approved as a drug. It has no approved indication and is not legally marketed as a pharmaceutical in the United States.
Is tesamorelin FDA approved?
Yes. Tesamorelin (Egrifta) was approved by the FDA in 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It is the only GHRH analogue with an approved indication for visceral fat reduction.
How does AOD 9604 work mechanistically?
AOD 9604 corresponds to amino acids 177 to 191 of the human growth hormone sequence. It is proposed to stimulate lipolysis and inhibit lipogenesis without meaningfully raising IGF-1, but this mechanism has been demonstrated primarily in rodent models. Human mechanistic data are sparse.
How does tesamorelin work?
Tesamorelin is a synthetic analogue of GHRH with a trans-3-hexenoic acid group added to the N-terminus for stability. It binds the GHRH receptor in the pituitary, stimulating pulsatile GH release and downstream IGF-1 elevation, which drives lipolysis in visceral adipose tissue.
Which has better human clinical evidence for fat loss?
Tesamorelin has substantially better human evidence. Phase 3 RCTs with hundreds of participants showed statistically significant visceral adipose tissue reductions measured by CT scan. AOD 9604 human data consist of small pilot studies with no large RCT published.
Does AOD 9604 raise IGF-1 or blood glucose?
Animal studies and the limited human pilot data suggest AOD 9604 does not significantly raise IGF-1 or fasting blood glucose. However, the absence of large human trials means this reassurance is based on low-quality evidence.
What are the main side effects of tesamorelin?
In phase 3 trials, common adverse events included injection site reactions, fluid retention, arthralgias, and peripheral edema. Tesamorelin can raise IGF-1 above the upper limit of normal in a proportion of patients and is contraindicated in active malignancy, pregnancy, and disrupted hypothalamic-pituitary axis.
Can AOD 9604 and tesamorelin be combined?
No published human data evaluate this combination. From a mechanistic standpoint they act on different targets, so additive lipolytic effect is plausible, but additive risks and interactions are entirely unstudied. Combining them would be experimental without clinical oversight.
What does AOD 9604 GRAS status actually mean?
GRAS status as a food ingredient means the FDA accepted that AOD 9604 was safe for use in food products at the concentrations studied. It does not confer drug approval, does not validate fat-loss efficacy, and does not apply to injectable formulations used in peptide therapy protocols.
How should tesamorelin be stored and handled?
Unopened tesamorelin vials should be refrigerated at 2 to 8 degrees Celsius and protected from light. After reconstitution, the solution should be used promptly. The trans-3-hexenoic acid modification improves stability relative to native GHRH but the reconstituted peptide still degrades meaningfully at room temperature over hours.
Is either peptide detectable on drug tests?
Tesamorelin is on the WADA prohibited list under GHRH analogues. AOD 9604 is also listed by WADA as a prohibited GH fragment. Both would be detected in anti-doping screens used in competitive sports, and use without a therapeutic use exemption constitutes a violation.
Sources
- Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension." Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322.
- U.S. Food and Drug Administration. "Egrifta (tesamorelin for injection) Prescribing Information." FDA.gov. Accessed 2026.
- Heffernan M, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001;142(12):5182-5189.
- Ng FM, et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone and Metabolic Research. 2000;32(3):87-91.
- U.S. Food and Drug Administration. GRAS Notice No. GRN 000612. AOD9604. 2014.
- World Anti-Doping Agency. "WADA Prohibited List 2024." wada-ama.org.
- U.S. Pharmacopeia. "General Chapter 1 Injections and Implanted Drug Products." USP-NF.